findmyKOL
Clinical trialNCT04365101TerminatedPhase 1/PHASE2Interventional

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

SponsorCelularity IncorporatedEnrollment7ARDSAnalgesicsAnti-infective AgentsAntimetabolites, AntineoplasticAntiviral AgentsCoronaviridae Infections+14 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uc Irvine

    Irvine, California, United States

  • Atlantic Health

    Morristown, New Jersey, United States

  • Atlantic Health

    Summit, New Jersey, United States

  • Multicare Health System

    Tacoma, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Sept 2020
Primary completion
30 Aug 2021
Completion
15 Feb 2023
Last update posted
26 Jun 2026
Registered enrollment
7
Registry id
NCT04365101

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.